Read + Share
Abou Chakra M, Myers AA, Duquesne I, Mott SL, et al. Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk
Non-Muscle-Invasive Bladder Cancer. Urol Pract 2026 Oct 23:101097UPJ0000000000001109.
PMID: 42909595
|
 |
|
Abou Chakra M, Myers AA, Duquesne I, Mott SL, et al. Timing of FDA-Defined Adequate BCG Therapy and Oncologic Outcomes in High-Risk
Non-Muscle-Invasive Bladder Cancer. Urol Pract 2026 Oct 23:101097UPJ0000000000001109.
PMID: 42909595
|
|
|
|